Latest news with #CateMcCanless
Associated Press
4 days ago
- Business
- Associated Press
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Jun 4, 2025-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46 th Annual Global Healthcare Conference in Miami, FL on Monday, June 9, 2025, at 3:20 p.m., ET A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit View source version on CONTACT: Harmony Biosciences Investor Contact: Brennan Doyle 484-539-9700 [email protected] Biosciences Media Contact: Cate McCanless 202-641-6086 [email protected] KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: RESEARCH NEUROLOGY BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE SOURCE: Harmony Biosciences Holdings, Inc. Copyright Business Wire 2025. PUB: 06/04/2025 08:05 AM/DISC: 06/04/2025 08:04 AM
Associated Press
18-02-2025
- Business
- Associated Press
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Feb 18, 2025-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 25, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), and reference passcode HRMYQ424. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit 484-539-9700 [email protected] Biosciences Media Contact: Cate McCanless 202-641-6086 SOURCE: Harmony Biosciences Holdings, Inc. Copyright Business Wire 2025.
